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ABSTRACT 21 
Robenacoxib and ketoprofen are acidic non-steroidal anti-inflammatory drugs (NSAIDs). Both 22 
are licensed for once daily administration in the cat, despite having short blood half-lives. This 23 
study reports the pharmacokinetic/pharmacodynamic (PK/PD) modelling of each drug in a feline 24 
model of inflammation. Eight cats were enrolled in a randomised, controlled, three period cross-25 
over study. In each period, sterile inflammation was induced by injection of carrageenan into a 26 
subcutaneously implanted tissue cage, immediately before the subcutaneous injection of 27 
robenacoxib (2 mg/kg), ketoprofen (2 mg/kg) or placebo. Blood samples were taken for 28 
determination of drug and serum thromboxane (Tx)B2 concentrations (measuring COX-1 29 
activity). Tissue cage exudate samples were obtained for drug and prostaglandin(PG)E2 30 
concentrations  (measuring COX-2 activity). Individual animal pharmacokinetic and 31 
pharmacodynamic parameters for COX-1 and COX-2 inhibition, were generated by PK/PD 32 
modelling. S(+) ketoprofen clearance scaled by bioavailability (CL/F) was 0.114 L/kg/h 33 
(elimination half-life =1.62 h). For robenacoxib, blood CL/Fwas 0.684 L/kg/h (elimination half-34 
life =1.13 h). Exudate elimination half-lives were 25.9 and 41.5 h for S(+) ketoprofen and 35 
robenacoxib, respectively. Both drugs reduced exudate PGE2 concentration significantly between 36 
6 and 36 h. Ketoprofen significantly suppressed (>97%) serum TxB2 between 4 min and 24 h, 37 
whereas suppression was mild and transient with robenacoxib. In vivo IC50COX-1/IC50COX-2 38 
ratios were 66.9:1 for robenacoxib and 1:107 for S(+) ketoprofen. The carboxylic acid nature of 39 
both drugs may contribute to the prolonged COX-2 inhibition in exudate, despite short half-lives 40 
in blood. 41 
INTRODUCTION 42 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) and have been 43 
used for many decades to alleviate inflammation-related pain in human and veterinary medicine. 44 
COXibs belong to a class of NSAIDs that selectively inhibit the COX isoform up-regulated in 45 
inflammation (COX-2), with much less inhibition of the constitutively expressed COX isoform 46 
(COX-1) responsible for the production of so-called “housekeeping” eicosanoids. Several 47 
COXibs were associated with an increased risk of myocardial infarction or stroke in man when 48 
evaluated against non-selective NSAID comparators and administered at recommended dose 49 
rates (Bombardier et al., 2000; Silverstein et al., 2000). However, lumiracoxib contrasted with 50 
other COXibs by displaying favourable cardiovascular and gastrointestinal safety profiles in a 51 
study incorporating more than 18,000 human patients (Farkouh et al., 2004).  52 
 53 
Despite a short plasma half-life (2 to 6.5 h) in man, lumiracoxib was authorised for once daily 54 
administration (Mysler, 2004), whereas rofecoxib and celecoxib were both administered twice 55 
daily, despite their long respective half-lives of 17 and 19 to 32 h (Vasquez-Bahena et al., 2010). 56 
The persistent clinical efficacy of lumiracoxib may be related to a prolonged residence of the 57 
drug in inflamed joints (Scott et al., 2004; Brune & Furst, 2007).  58 
 59 
Robenacoxib is a structural analogue of lumiracoxib, licensed for use in cats (and dogs). Both 60 
drugs are structurally related to diclofenac (Fig. 1), containing a carboxylic acidic function 61 
instead of the methylsulphone (as for rofecoxib) or the sulphonamide (as for celecoxib) groups 62 
characteristic of first generation COXibs.  Robenacoxib has a short blood half-life of 1.9 h after 63 
subcutaneous administration in the cat (Pelligand et al., 2012b) but is as effective as an analgesic 64 
as meloxicam (half-life 37 h) for at least 22 h post-operatively (Kamata et al., 2012).  65 
 66 
Ketoprofen is a COX-1 selective NSAID (Fig. 1), licensed for once daily administration in man 67 
and cats (Warner et al., 1999; Schmid et al., 2010) despite short elimination half-lives for the 68 
eutomer S(+) ketoprofen of 1.2 h in the cat and 2 to 3 h in man (Rudy et al., 1998; Lees et al., 69 
2003). 70 
We hypothesised that robenacoxib and ketoprofen would be similarly effective as anti-71 
inflammatory drugs in a feline model of inflammation, despite the differences in COX 72 
selectivity, because of similar concentration-time profiles and potency for COX-2 inhibition. 73 
Several models of inflammation have been developed in the cat (Giraudel et al., 2005b; 74 
Pelligand et al., 2012a) but only the carrageenan-based tissue cage model of Pelligand et al. 75 
(2012a) allows serial measurement of NSAID concentrations in blood and at the site of 76 
inflammation, as well as determination of the magnitude and time-profiles of COX-1 and COX-2 77 
inhibition. We have previously described exudate sampling from these cages for serial 78 
measurement of NSAID and Prostaglandin(PG)E2 concentrations, the latter inflammatory 79 
mediator as a surrogate of COX-2 activity, together with blood sampling for measurement of 80 
serum thromboxane(Tx)B2 as a surrogate of COX-1 activity (Pelligand et al., 2012a; Pelligand et 81 
al., 2012b). The model further enables calculation of pharmacodynamic parameters of NSAIDs, 82 
namely Imax (efficacy), IC50 (potency) and n (slope of the concentration-effect relationship). 83 
These parameters are used to calculate dosage regimens for clinical use (Lees et al., 2004).  84 
 85 
The aims of this study were to: (i) compare the pharmacokinetic and the pharmacodynamic 86 
profiles of robenacoxib and ketoprofen in feline blood and exudate; (ii) compare in vivo IC50 87 
COX-2, ex vivo IC50 COX-1 and COX inhibition selectivity for each drug; and (iii) compare and 88 
contrast the pharmacokinetic and pharmacodynamic profiles of two carboxylic acid sub-groups 89 
of NSAIDs, the profens and COXibs, in the cat.  90 
 91 
MATERIALS AND METHODS 92 
Animals 93 
Eight domestic short hair cats (all neutered, 5 males and 3 females, aged 1 to 3 years), weighing 94 
4.0±0.39 kg, were enrolled into the study after an acclimatisation period of one month. Health 95 
checks were performed before the start of each sampling period. Between study periods, the cats 96 
were grouped housed altogether. They were fed a dry commercial diet (RF23, Royal Canin, 97 
Aimargues, France) in two equal portions daily, based on their metabolic requirements. Drinking 98 
water was available ad libitum. The room was lit from 7.00 am to 7.00 pm. 99 
 100 
The study complied with United Kingdom Home Office regulations (Project License Number 101 
70/6132). The protocol was approved by the Royal Veterinary College Ethics and Welfare 102 
Committee. All tissue cages were electively removed under general anaesthesia 6 months after 103 
implantation, before the cats were re-homed, as no long lasting sequelae resulted from the 104 
protocol.  105 
 106 
Animal preparation and induction of inflammation 107 
Four tissue cages were implanted surgically in each cat, as previously described (Pelligand et al., 108 
2012b). Briefly, medical grade silicone cylindrical tissue cages (SF Medical, Fresno, CA, USA) 109 
were prepared to the following dimensions: 70 mm length, 15.9 mm external diameter, 12.7 mm 110 
internal diameter (6.7 cm3 internal volume) with 12 holes at each pole providing a total surface 111 
exchange area of 3.0 cm2 per cage. They were sterilised and surgically inserted subcutaneously, 112 
under isoflurane (IsoFlo, Abbott Animal Health, Maidenhead, UK) general anaesthesia, parallel 113 
to the vertebral column in the flank and thorax areas. Analgesia was provided intra- and post-114 
operatively as described by Pelligand et al. (2012a). The tissue cages were flushed with sterile 115 
saline under general anaesthesia 7 weeks after implantation to remove any remaining cellular 116 
debris and subsequently used experimentally, not earlier than 10 weeks after implantation. On 117 
the day before dosing, the fur over the cages was clipped and a double-lumen catheter 118 
(CS15402E, Arrow International Ltd, Uxbridge, UK) was inserted in a jugular vein under 119 
general anaesthesia (Pelligand et al .2012a).  120 
 121 
On day 1 of each period, 1 mL of a 2% sterile carrageenan solution (Viscarin, FMC biopolymers, 122 
Philadelphia, PA, USA)  was injected into a naïve tissue cage (Pelligand et al., 2012b) and this 123 
tissue cage was used to harvest exudate in that period. A different tissue cage was stimulated for 124 
each subsequent period.  125 
 126 
Experimental design 127 
The experiment was conducted as a three-period, three-sequence, cross-over with 28 day 128 
washout intervals. The treatment for the first period was allocated following a randomised 129 
blocked design and the sequence of treatments for the subsequent periods followed an 130 
incomplete latin square design. All cats received each of the treatments. The three treatments, 131 
administered subcutaneously in the neck area, were: robenacoxib 2 mg/kg (Onsior 2.0% solution, 132 
Novartis Animal Health, Basel, Switzerland); racemic ketoprofen 2 mg/kg (Ketofen 1% solution, 133 
Merial Animal Health, Harlow, Essex,  UK); and 0.9% saline (0.1 mL/kg) as placebo. On each 134 
test day, the cats were fed 2 h before dosing and again after the final blood sample of the day (12 135 
h after dosing). The carrageenan-stimulated cages were sampled (1.0 to 1.3 mL of exudate on 136 
each occasion) before and at 3, 6, 9, 12, 24, 34, 48, 72, 96 and 120 h after carrageenan injection 137 
(11 serial samples from the same cage). Samples were transferred immediately to 1.5 mL 138 
Eppendorf tubes containing 10 µg indomethacin (Sigma Aldrich, Poole, Dorset, UK) to prevent 139 
artefactual ex vivo eicosanoid generation. The tube was mixed by gentle inversion and placed on 140 
ice until centrifugation at 1000 g, 4° C for 10 min. The supernatant was aliquoted and frozen at -141 
80°C prior to measurement of exudate PGE2 and concentrations of ketoprofen or robenacoxib. 142 
 143 
Blood samples (maximum 1.5 mL per sample) were taken from the distal port jugular catheter 144 
before dosing and at 4, 15, 30 min, then 1, 1.5, 2, 3, 4, 6, 9, 12, 24 and 48 h after dosing. An 145 
aliquot of each blood sample (0.2 mL) was allowed to clot in a glass tube (Chromacol, Welwyn 146 
Garden City, Herts., UK) whilst incubated in a water bath at 37º C for 1 h then centrifuged (1500 147 
g, 4º C, 10 min) and the supernatant stored at -80º C prior to measurement of serum TxB2. The 148 
remainder of the sample (1.3 mL) was transferred into an EDTA tube (International Scientific 149 
Supplies Ltd., Bradford, Yorks., UK) for blood robenacoxib measurement or a heparin tube for 150 
plasma ketoprofen measurement and stored at -80º C. 151 
 152 
To ensure accuracy of pharmacokinetic calculations, cats were weighed on the day of catheter 153 
placement, actual injected doses were calculated by weighing syringes before and after injection 154 
and actual rather than nominal times of blood sampling were used.  155 
 156 
Measurement of NSAID concentrations 157 
Plasma (ketoprofen), blood (robenacoxib) and  exudate  (both drugs) were spiked with known 158 
drug concentrations to establish standard curves, and quality controls (QCs) were prepared and 159 
dispersed over the sequence of unknown samples, to monitor the overall performance of each 160 
analytical method. The percentage of back-calculated concentrations of standards within ±15% 161 
of their nominal value and the percentage of QCs within ±15% of their theoretical value were 162 
calculated. Imprecision (indicator of between day repeatability) was expressed as the coefficient 163 
of variation (CV%) between standard concentrations run on different days. Inaccuracy was 164 
expressed as the deviation of the mean (% Relative Error) from the theoretical concentration 165 
spiked into blank matrix. 166 
 167 
Robenacoxib concentrations in feline blood were measured using a sensitive analytical method, 168 
as described by Jung et al. (2009). Briefly, the method involved an initial analysis by HPLC-UV, 169 
covering the range of 500-20,000 ng/mL and, if required, a subsequent analysis by LC-MS, 170 
covering the range of 3-100 ng/mL for blood. Depending on the results obtained by UV analysis, 171 
samples were diluted if necessary in order not to exceed a concentration of 100 ng/mL in the MS 172 
method. The same method was used for exudate, except that 250 µL of sample were extracted 173 
and diluted two-fold with water, instead of using 500 µL of blood. For blood with the MS 174 
method, the lower and upper limits of quantification were 3 and 100 ng/mL, respectively. Since 175 
the exudate was diluted two fold, the MS method had a range of 6-200 ng/mL for exudate in the 176 
initial method validation, but this was extended subsequently to 3.5 – 200 ng/mL, as it was 177 
established during the analysis that reliable results were obtained at the lower end of the range. 178 
For robenacoxib, inaccuracy was less than 10.4% and imprecision was less than 9.3%.  179 
 180 
R(-) ketoprofen and S(+) ketoprofen concentrations were measured in exudate and plasma by 181 
liquid chromatography mass-spectrometry (API 2000 LC/MS/MS system, Applied Biosystems, 182 
Ontario, Canada). The method, previously validated for cat and piglet plasma (Fosse et al., 2011 183 
and Hormazábal, unpublished data), had lower and upper limits of quantification of 10 and 8,000 184 
ng/mL for both matrices. After extraction, filtration and centrifugation of 0.5 mL 185 
plasma/exudate, 50 µL of the supernatant was separated on a 100 x 4.6 mm Chirobiotic R 186 
column packed with 5 µm ristocetin A particles (Chirobiotic R, Astec, NJ, USA) at 18°C. The 187 
mobile phase comprised 46% of 10 nM ammonium acetate (containing 0.3% formic acid) and 188 
54% methanol. Flow rate was 0.6 mL/min. A guard column with similar sorbent was used (20 x 189 
4.0mm). Average retention times were 4.9 and 5.4 min for S(+) and R(-) ketoprofen, 190 
respectively. The detector operated in multiple reactions monitoring (MRM) mode and collected 191 
ion data in positive mode. The protonated molecular ion was m/z 255. The product ion m/z 209.1 192 
was used for screening and quantification, while the ratios with the product ion m/z 105.2 were 193 
used for confirmation of the identity. For ketoprofen enantiomers, inaccuracy was less than 1.3% 194 
and imprecision was less than 0.7%. 195 
 196 
Pharmacodynamic measurements 197 
In vivo generation of exudate PGE2 and ex vivo generation of serum TxB2 were used as 198 
surrogates for COX-2 and COX-1 activities, respectively. Although the main source of TxB2 in 199 
serum is platelet COX-1, a minor contribution from COX-2 or from other cells cannot be 200 
completely excluded. Additionally, COX-1 may contribute to the synthesis of PGE2 in exudate 201 
(Nantel et al., 1999; Wallace et al., 1999), but the magnitude of this production is likely to be 202 
negligible, based on the fact that COX-1 is not induced in carrageenan inflammatory models 203 
(Tomlinson et al., 1994).  204 
 205 
Serum TxB2 and exudate PGE2 concentrations were measured with competitive radio-206 
immunoassays, adapted from Higgins et al. (1984) as described in a previous validation paper 207 
(Pelligand et al., 2012a). Two concentrations of pooled samples were aliquoted, and used as 208 
quality controls, dispersed over the sequences of unknown samples to calculate inter- and intra-209 
assay variability. Exudate PGE2 intra-assay variability was 3% for the high control concentration 210 
(2.9 ng/mL) and 23.9% for the low control concentration (0.13 ng/mL). Inter-assay variability 211 
was 2.1% for the high control and 31% for the low control concentrations. Serum TxB2 intra-212 
assay variability was 7.2% for the high control (235.1 ng/mL) and 13.2% for the low control 213 
(56.5 ng/mL) concentrations. Inter-assay variability was 2.3% and 11.3% for the high and low 214 
control concentrations, respectively. All validation data complied with analytical 215 
recommendations guidelines (Kelley & DeSilva, 2007; Viswanathan et al., 2007) except for 216 
PGE2 inter-assay variability. Therefore, all samples from the same cats were always analysed in 217 
the same batch. 218 
 219 
Pharmacokinetic data analysis 220 
Pharmacokinetics and PK/PD modelling were performed by the least-squares regression method, 221 
using commercial software (WinNonlin version 5.2, Pharsight Corporation, Mountain View, CA, 222 
USA). Goodness of fit and selection of the appropriate model were evaluated using the Akaike 223 
Information Criterion estimate (Yamaoka et al., 1978) and by visual inspection of the fitted 224 
curves and residuals. 225 
Blood robenacoxib and plasma ketoprofen enantiomer concentrations C(t) were fitted for each 226 
cat using an equation corresponding to drug disposition in a two-compartmental model with 227 
absorption phase (subcutaneous administration, Eq. 1): 228 
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where λ1 and λ2 are the initial and terminal slopes (/h), Y1 and Y2 the intercepts on the Y axis 230 
(ng/mL), when C(t) is plotted on a semi-logarithmic scale, ka is the first-order absorption rate 231 
constant (/h) and tlag the absorption lag time after subcutaneous administration. Data were 232 
weighted by the reciprocal of the estimated value for blood or plasma concentration when 233 
necessary. 234 
 235 
Exudate concentrations of robenacoxib or ketoprofen enantiomers Ce(t) were fitted for the data 236 
from each cat using an equation corresponding to drug disposition in a bicompartmental model 237 
with an absorption phase after dose normalisation (Eq. 2): 238 
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where λe1 and λe2 are the initial and terminal slopes (/h), Ye1 and Ye2 the intercepts on the Y axis 240 
(ng/mL) when Ce(t) is plotted on a semi-logarithmic scale, and kea is the first-order invasion rate 241 
constant in exudate (/h). No weighting was applied to the data for fitting. It was assumed that 242 
only a negligible amount of each NSAID gained access to the tissue cage and that the 243 
pharmacokinetics in exudate had no effect on the time-course of drug disposition in the rest of 244 
the body. 245 
 246 
Pharmacokinetic parameters were generated for robenacoxib (in blood and exudate) and S(+) and 247 
R(-) ketoprofen (in plasma and exudate) by non-compartmental analysis for individual cats, as 248 
follows:  Maximum NSAID concentration, Cmax, Time of maximum NSAID concentration, Tmax, 249 
Area under NSAID concentration-time curve, AUC0-inf, Area under first the Moment Curve, 250 
AUMC0-inf, NSAID Mean Residence Time (MRT) = AUMC0-inf /AUC0-inf, NSAID terminal half-251 
life, t½=ln(2)/λz, where λz is the slope of the drug elimination phase, computed by linear 252 
regression of the logarithmic concentration versus time curve during the elimination phase, 253 
NSAID clearance scaled by bioavailability (F), CL/F= dose/(F x AUC0-inf), where F is the 254 
bioavailability for extravascular administration, Apparent volume of distribution of NSAID 255 
during the elimination phase, Varea/F = (dose/F)/(AUC0-inf x λz). 256 
 257 
Pharmacodynamic data analysis and PK/PD modelling 258 
A user program was purposely written in WinNonlin for PK/PD modelling. The equations of 259 
robenacoxib and S(+) ketoprofen enantiomer disposition in blood/plasma C(t) or in exudate Ce(t) 260 
were obtained by compartmental pharmacokinetic analysis by fitting equations (1) or (2), 261 
respectively, to the observed data. Individual pharmacokinetic parameters were entered as 262 
constants to solve the PK/PD models in a 2 stages analysis (Giraudel et al., 2005a). 263 
In vivo generation of exudate PGE2 was used as a surrogate for COX-2 activity in order to carry 264 
out PK/PD modelling of the NSAIDs in exudate (Lees et al., 2004). An indirect response model 265 
described by Pelligand et al. (2012b)  was used to model the effect of robenacoxib and S(+) 266 
ketoprofen on exudate PGE2 production. The model did not include the R(-) enantiomer, as it 267 
was considered to be devoid of activity on cyclooxygenase at the concentrations achieved. 268 
Indeed, S(+) ketoprofen is the eutomer of the S(+)/R(-) ketoprofen enantiomeric pair (Lees et al., 269 
2003). The response is indirect because it is the consequence of a dynamic physiologic 270 
equilibrium between PGE2 production after carrageenan injection, the natural clearance of PGE2 271 
from exudate and the reversible inhibition of COX-2 by NSAIDs, preventing the build-up of 272 
PGE2 in exudate as in Equation 3 (Dayneka et al., 1993):  273 
                    2outin
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where dPGE2/dt (ng/mL/h) is the rate of change of PGE2 concentration in exudate, Kout (/h) is a 275 
first order parameter expressing PGE2 disappearance rate and Kin(t) (ng/mL/h) is a zero-order 276 
time-function expressing PGE2 production rate. Kin is considered as a time-dependent parameter, 277 
influenced by carrageenan administration and NSAID concentration (in the periods when 278 
administered). To express the action of carrageenan on Kin, a stimulation function (named 279 
stimulPLACEBO and stimulNSAIDs was selected as Eq. 4 and Eq. 5 for the placebo and NSAID 280 
periods, respectively: 281 
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where k1 and k2 are the first-order rate constants (/h) describing the time-development of the 284 
carrageenan stimulation, carrag is a scalar factor, and tlag1 and tlag2 represent the delays in the 285 
onset of inflammation for the placebo and NSAID periods, respectively. Consequenlty, tlag is 286 
the only difference between stimulPLACEBO and stimulNSAIDs function. Equation 4 and Eq. 5 287 
assume that the effect of carrageenan stimulation of COX builds up progressively (as reflected 288 
by k2) after injection, then steadily decreases (as reflected by k1) (Lepist & Jusko, 2004).  289 
It was assumed that robenacoxib and ketoprofen suppressed the carrageenan action in exudate 290 
through an Imax function (Lees et al., 2004) of the form (Eq. 6): 291 
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I(t) is a time-dependant scalar. Imax is a scalar fixed to 1, expressing the fact that robenacoxib can 293 
totally inhibit carrageenan pro-inflammatory effect. IC50 expresses the NSAID potency against 294 
carrageenan effect; n is the Hill exponent expressing the steepness of the NSAID concentration 295 
versus effect curve. Finally, incorporating Eq. 4 (placebo) or Eq. 5 and Eq. 6 (NSAID) in the 296 
general Eq. 3, the time development of PGE2 concentration in exudate was described by Eq. 7 297 
(placebo) and Eq. 8 (NSAID): 298 
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The time-courses of exudate PGE2 were modelled simultaneously for placebo and robenacoxib, 301 
then placebo and S(+) ketoprofen, as the equations for placebo and NSAIDs share several 302 
common parameters in the same cat (Kin, Kout and carrag, k1 and k2). Nine parameters were 303 
estimated by the model, namely kin, carrag, k1, k2, tlag1, tlag2, kout IC50 and n.  304 
 305 
Ex vivo generation of serum TxB2 was used as a surrogate marker of COX-1 activity for PK/PD 306 
modelling. The NSAID concentration in the central compartment produced an inhibition of 307 
serum TxB2 synthesis according to the following sigmoid Imax model selected to fit the serum 308 
TxB2 data (Eq.9): 309 
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where I0 (t)is the baseline serum TxB2 concentration (ng/mL) for an individual cat, Imax (%) is the 311 
percentage of maximal TxB2 suppression (corresponding to the lower limit of quantification of 312 
the assay) relative to I0(t), IC50 (ng/mL) is the concentration that achieves half of the maximal 313 
TxB2 suppression and n is the slope of the NSAID concentration-effect curve. In most cats, the 314 
serum TxB2 concentration had drifted below baseline by the end of the period when placebo was 315 
administered, as also reported in a previous study (Pelligand et al., 2012b). This drift of baseline 316 
throughout the course of the experiment was modelled as (Eq. 10): 317 
 tdI)t(I 00         (Eq. 10) 318 
where d represents the slope of the baseline function for an individual cat and I0 the initial TxB2 319 
concentration during the treatment period (Ollerstam et al., 2006). The slope was calculated for 320 
each cat by linear regression of the serum TxB2 concentration after placebo administration. As 321 
blood samples were collected for 48 h during the ketoprofen period but only for 24 h after 322 
placebo and robenacoxib dosing, the drift was not applied between 24 h and 48 h (Eq. 11): 323 
 24dI)h24t(I 00        (Eq. 11) 324 
 325 
Calculation of potency indices and estimation of extent of COX-2 blockade centrally 326 
Individual concentration-effect curves for (i) in vivo inhibition of COX-2 and (ii) ex vivo 327 
inhibition of COX-1 were simulated using calculated pharmacodynamic parameters expressing 328 
the maximal effect (Imax), potency (IC50) and steepness of the NSAIDs concentration-effect 329 
relationship (n). An average curve for COX-1 and COX-2 was fitted to the individual curves 330 
previously simulated (naïve pooled approach) using the same Hill equation (Giraudel et al., 331 
2005b; Pelligand et al., 2012b). The corresponding average parameter values (aIC50 and an) and 332 
95% confidence intervals were derived to calculate the selectivity indicesto describe the relative 333 
in vivo selectivity.. Finally, the predicted percentage of COX-1 inhibition was calculated for 50, 334 
80, 95 and 99% inhibition of COX-2. 335 
  336 
Statistical analysis 337 
Figures and potency curve fitting were computed using Prism version 5 (GraphPad, La Jolla, 338 
CA, USA). Statistics were performed with PASW Statistics (version 17, IBM, New York, USA) 339 
using a linear mixed model for PGE2 and TxB2. Treatment, time and treatment-time interaction 340 
were entered as fixed effects and cat was entered as a random effect. Time was nested within 341 
treatment and cat, a first order autoregressive covariance structure (AR1) was used (Littell et al., 342 
1998; Kristensen & Hansen, 2004). The normality assumption of the residuals was assessed by 343 
visual inspection and was verified after a log transformation of exudate PGE2 and serum TxB2 344 
concentrations. All reported P values are two-tailed, with statistical significance defined as P 345 
<0.05. In the post hoc tests, multiple analyses were corrected using the Bonferroni method. 346 
Arithmetic, geometric and harmonic means are presented (in tables only) as mean ± SD, mean 347 
[95% Confidence Interval] and mean ± pseudoSD (obtained by the Jackknife method), 348 
respectively (Lam et al., 1985). 349 
 350 
 351 
RESULTS  352 
Pharmacokinetics   353 
Pharmacokinetic parameters for plasma ketoprofen and blood robenacoxib concentrations are 354 
summarised in Table 1. The plasma concentration-time curve of ketoprofen was best described 355 
by a bicompartmental model with first order absorption for the S(+) enantiomer and a 356 
monocompartmental model with first order absorption for the R(-) enantiomer (Fig. 2). Peak 357 
plasma concentrations were 4,306 ng/mL for S(+) ketoprofen (Tmax= 0.53 h) and 3,787 ng/mL 358 
for R(-) ketoprofen (Tmax= 0.25 h). Apparent clearances (CL/F) were 0.114 L/kg/h for S(+) 359 
ketoprofen and 0.325 L/kg/h for R(-) ketoprofen. Terminal elimination half-life was longer for 360 
S(+) ketoprofen (t½=1.62 h, MRT=1.7 h) than for R(-) ketoprofen (t½=0.44 h, MRT=0.7 h).  361 
 362 
The blood concentration-time curve of robenacoxib was best described by a bicompartmental 363 
model with first order absorption (Fig. 3). Peak plasma concentration of 1,313 ng/mL was 364 
reached after 0.9 h and the mean absorption tlag was 0.05 h. Apparent blood robenacoxib 365 
clearance was moderate (0.684 L/kg/h) (Toutain & Bousquet-Melou, 2004) and elimination half-366 
life was 1.13 h. 367 
 368 
Pharmacokinetic parameters for exudate are summarised in Table 2. The exudate ketoprofen 369 
enantiomer concentrations followed a bi-exponential decay (Fig. 2). Harmonic mean penetration 370 
half-lives of S(+) and R(-) ketoprofen in exudate were 2.93 h and 2.06 h, respectively. Maximum 371 
exudate concentrations were reached at 7.9 h and 6.0 h after injection for S(+) and R(-) 372 
ketoprofen, respectively. The mean peak exudate concentration of S(+) ketoprofen was 169 373 
ng/mL, and that of R(-) ketoprofen was 44 ng/mL. Elimination half-lives from tissue cages were 374 
25.9 h for S(+) and 22.5 h for R(-) ketoprofen, accounting for correspondingly long MRTs of 375 
35.9 h and 36.2 h.  376 
 377 
Exudate robenacoxib concentration followed a bi-exponential decay (Fig. 3 and 4). One cat (D2) 378 
had peak robenacoxib exudate concentration (351 ng/mL) that was approximately 4-fold higher 379 
than the average Cmax value observed in the other seven cats. However, its exudate 380 
concentrations were similar to those observed in the other seven cats by the 12th hour postdose. 381 
Since a similar inconsistency was not observed when this cat was administered ketoprofen and 382 
because this cat did not behave as an outlier during the pharmacodynamics or blood level PK 383 
component of this investigation, it was assumed that these high initial robenacoxib 384 
concentrations were a function of experimental error. Accordingly, cat D2 was excluded from 385 
the robenacoxib exudate evaluations. However, it should be noted that in the absence of a 386 
confirmed source of this error, it is impossible to exclude the possibility that the exudate profiles 387 
associated with cat D2 reflect an idiosyncrasy that may exist in a subpopulation of cats. That 388 
said, the maximal robenacoxib concentration for the seven other cats was 85.2 ng/mL, attained at 389 
8.1 h after dosing. Harmonic mean penetration half-life of robenacoxib in inflammatory exudate 390 
was 4.9 h. Exudate elimination half-life and MRT were 41.5 h and 45.7 h, respectively. 391 
 392 
 393 
Pharmacodynamics 394 
Both ketoprofen and robenacoxib reduced exudate PGE2 concentrations significantly between 6 395 
and 36 h (Fig. 5). Maximum PGE2 inhibition, at 9 h, was 92.1% for robenacoxib and 90.9% for 396 
ketoprofen.  397 
 398 
Maximal TxB2 suppression with robenacoxib was 51.2 % at 2 h and this was the only time when 399 
the effect of robenacoxib was significantly different from placebo (Fig. 6). TxB2 had returned to 400 
placebo level at 3 h. With ketoprofen, serum TxB2 inhibition occurred rapidly, commencing 4 401 
min after injection (97.1%) and suppression was maximal (97.9%) at 1 h (Fig. 6). Compared to 402 
placebo, ketoprofen significantly suppressed serum TxB2 between 4 min and 24 h. Serum TxB2 403 
was 11.8% and 58.2% of the placebo concentration at 24 and 48 h, respectively. 404 
 405 
 406 
PK/PD analysis 407 
For COX-2 inhibition, the PK/PD model for estimation of pharmacodynamic parameters gave 408 
good results in 6 of 8 cats for both S(+) ketoprofen and robenacoxib. In two cats, the model did 409 
not converge, because exudate PGE2 concentrations were reduced below the limit of 410 
quantification of the assay or did not recover to the levels in the placebo group within 120 h. 411 
Means of individual estimates of the pharmacodynamic COX-2 parameters for the carrageenan 412 
model, and after administration of ketoprofen and robenacoxib, are presented in Table 3. The 413 
geometric mean COX-2 IC50 was 44.7 ng/mL (0.14 µM) for robenacoxib and 45.0 ng/mL (0.18 414 
µM) for S(+) ketoprofen.  415 
 416 
PK/PD modelling for COX-1 was successful in all animals with robenacoxib and in 6 of 8 cats 417 
with S(+) ketoprofen. For the latter, in two cases, the number of blood samples was too low to 418 
allow bi-compartmental fitting of plasma concentrations and thus prevented PK/PD modelling. 419 
Individual geometric mean IC50COX-1 was 2,951 ng/mL (1.31 µM) for robenacoxib and 0.17 420 
ng/mL (0.67 nM) for S(+) ketoprofen (Table 4). Imax was 97.3 % for S(+) ketoprofen and 96.8 % 421 
for robenacoxib. 422 
 423 
Individual concentration-effect curves were simulated using the pharmacodynamic parameters 424 
aforementioned. Average pharmacodynamic parameters (aImax, aIC50 and an) for S(+) ketoprofen 425 
and robenacoxib for inhibition of COX-1 in serum and COX-2 in exudate were calculated by 426 
naïve pooled data analysis (Table 5 and Fig. 7). The concentration-effect curves for COX-1 427 
required re-scaling to a maximal effect of 100%. The aIC50 values for COX-1 were 0.45 and 2,56 428 
ng/mL for S(+) ketoprofen and robenacoxib and the slopes (an) were 0.66 and 0.87, respectively. 429 
Corresponding aIC50 values for COX-2 were 48.5 and 38.2 ng/mL for S(+) ketoprofen and 430 
robenacoxib, respectively, and corresponding slopes were 1.04 and 1.46.  431 
 432 
Three categories of indices were used to describe the selectivity of robenacoxib, determined by 433 
simultaneous fitting of individual percentage inhibition values from COX-1 and COX-2 assays 434 
(Table 6). The IC50COX-1/IC50COX-2 ratio was 1:107 for S(+) ketoprofen and 66.9:1 for 435 
robenacoxib. The selectivity of robenacoxib for COX-2 was confirmed at virtually maximal 436 
inhibition, as IC99COX-1/IC99 COX-2 was 585:1. The IC20 COX-1/IC80 COX-2 ratio was 1:3,260 437 
for S(+) ketoprofen and 1.4:1 for robenacoxib. Predicted percentage inhibitions of COX-1 versus 438 
COX-2 are illustrated in Fig. 8; the inhibition of COX-1 by S(+) ketoprofen would be almost 439 
maximal for all COX-2 inhibition percentages between 50 and 99%, whereas only 28.2% of 440 
COX-1 activity would be inhibited by robenacoxib at 99% COX-2 inhibition. 441 
 442 
 443 
DISCUSSION 444 
 445 
S(+) ketoprofen was the predominant enantiomer in the cat,  as previously reported for the dog, 446 
rat and horse (Foster & Jamali, 1988; Delatour et al., 1993; Landoni & Lees, 1995a). Chiral 447 
inversion of R(-) to S(+) ketoprofen occurs in the liver, so that the R(-) enantiomer, although 448 
itself of very low potency, is a pro-drug. Therefore, the apparent clearance of R(-) ketoprofen 449 
incorporates both elimination and inversion to the S(+) eutomer. Consequently, the drug input 450 
for S(+) ketoprofen comprises both the administered drug and S(+) ketoprofen formed by chiral 451 
inversion. The inversion rate has been calculated in the cat by separate administration of each 452 
enantiomer (Castro et al., 2000; Lees et al., 2003). Simultaneous enantiomer pharmacokinetic 453 
modelling was not possible, as the inversion rate could not be identified from the data of the 454 
present study. This study confirmed the short half-life of both ketoprofen enantiomers in the cat. 455 
The pharmacokinetics of robenacoxib after subcutaneous administration was also consistent with 456 
the findings from previous studies (Pelligand et al., 2012b; King et al., 2013), with a short 457 
elimination half-life (1.1 h).  458 
 459 
Despite having short elimination half-lives in blood, ketoprofen and robenacoxib demonstrated 460 
marked negative hysteresis. Both drugs suppressed exudate PGE2 significantly for up to 36 h. 461 
The likely explanation is accumulation of drugs in and slow clearance from the tissue cage. It 462 
would have been relevant to test this hypothesis by directly injecting the test article into the 463 
tissue cages. The IC50 COX-2 for robenacoxib was somewhat higher at 38.2 ng/mL (0.117 µM) 464 
in the present study compared with 14.1 ng/mL (0.043 µM) reported in Pelligand et al. (2012b). 465 
For COX-1, the difference for robenacoxib between the two studies was minimal, with IC50 466 
COX-1 of 2,557 ng/mL (7.81 µM) in the present study and 2,416 ng/mL (7.38 µM) in the 467 
previous investigation. 468 
 469 
The persistence and duration of effect in exudate of ketoprofen enantiomers were similarly long  470 
as for robenacoxib. For 2-arylpropionates in general, and for ketoprofen in particular, COX 471 
inhibition activity resides almost exclusively with the S(+) enantiomer (Hayball et al., 1992; 472 
Suesa et al., 1993; Landoni et al., 1996) in several species including the cat. It is, indeed, 473 
probable that COX inhibition in the cat after R(-) ketoprofen administration is attributable solely 474 
to the S(+) enantiomer formed in vivo by chiral inversion (Lees et al., 2003). It was therefore 475 
justified, in this study, to conduct PK/PD modelling solely on S(+) ketoprofen concentration.  476 
 477 
The IC50 COX-2 for S(+) ketoprofen of 48.5 ng/mL (0.191 µM) was very similar to the  IC50  for 478 
robenacoxib in the present study (38.2 ng/mL) but was lower than the IC50 reported by Schmid et 479 
al. (2010) in in vitro whole blood assays: 119.9 ng/mL (0.472 µM). In serum, the ex vivo IC50 for 480 
COX-1 in the present study was 0.454 ng/mL (0.0018 µM) which was lower than the IC50 of 481 
5.92 ng/mL (0.023 µM) reported by Schmid et al. (2010) in in vitro assays. Inter-laboratory 482 
differences in experimental methodology (ex vivo versus in vitro) and differences in modelling 483 
techniques are well recognised as the basis for differing results, even of this relatively high 484 
magnitude (Warner et al., 1999). In consequence, we report an IC50 COX-1 / IC50 COX-2 ratio of 485 
1:107, which is lower than that obtained by Schmid et al. of 1:20. Despite these numerical 486 
differences, both studies confirm that ketoprofen is COX-1 selective in the cat. The time-course 487 
of inhibition of TxB2 with ketoprofen was similar to that reported after intravenous 488 
administration of 2 mg/kg racemic ketoprofen (Lees et al., 2003).  489 
 490 
The present data indicate that ketoprofen and robenacoxib exhibit similar pattern for distribution 491 
to a site of acute inflammation, whilst possessing opposite selectivities for inhibition of COX 492 
isoforms, ketoprofen for COX-1 and robenacoxib for COX-2. As discussed by (Brune & Furst, 493 
2007), the first generation selective COX-2 inhibitors (sulphonamides and methylsulphones) 494 
combined reduced gastrointestinal toxicity with prolonged inhibition of constitutively-expressed 495 
COX-2 in the vascular wall and kidney. This may explain, at least partially, the reported 496 
toxicities of these COXibs with long terminal half-lives and large volumes of distribution. It is 497 
therefore likely that tissue selectivity is a potential advantage of second generation COXibs 498 
(carboxylic acids) with shorter elimination half-lives. If these drugs exert only a short duration of 499 
action on constitutively expressed COX-2 in the central pharmacokinetic compartment, this 500 
might provide a higher safety profile, for example for cardiovascular and renal side-effects. As 501 
developed in our laboratory, the tissue cage model has allowed investigation of the distribution 502 
of robenacoxib and ketoprofen (selected for this study for both their differing COX inhibition 503 
profiles and long durations of action despite short half-lives in the central pharmacokinetic 504 
compartment) to a site of acute inflammation. It may be regarded as an appropriate  model to 505 
further our understanding of other carboxylic acid NSAIDs,  with similar chemical structures and 506 
pharmacokinetic profiles, such as lumiracoxib (COX-2 selective)  and  diclofenac (COX non-507 
selective) (Fig. 8) (Brune & Furst, 2007). 508 
 509 
It should, however, be noted that all tissue cage models are “model dependent”, in that drug 510 
diffusion into and from exudate in the cage is influenced by tissue cage geometry (including 511 
surface area), a lack of physiological drainage as for the synovial fluid lymph drainage, as well 512 
as drug molecule properties, including protein binding, pKa and lipid solubility. Therefore, tissue 513 
cage models cannot mimic either accurately or quantitatively all clinical circumstances. 514 
Nevertheless, it is of interest to note that lumiracoxib accumulated in inflamed joints in humans 515 
and its concentration was maintained in excess of plasma concentrations  for up to 18 h after 516 
dosing  (Scott et al., 2004). Similarly, ketoprofen penetrated readily into acutely inflamed joints 517 
of the horse. At one h after dosing the concentration in synovial fluid was six times higher in 518 
inflamed compared to non-inflamed joints (Owens et al., 1994). On the other hand, 519 
concentrations of etoricoxib (a coxib of the sulphonamide group) in wound fluids did not exceed 520 
plasma concentrations after pre-emptive administration before hip surgery (Renner et al., 2010; 521 
Renner et al., 2012). 522 
 523 
It is unlikely that the slow clearance of ketoprofen and robenacoxib from tissue cages was 524 
limited by passive diffusion. This is suggested by serum and exudate clearance data. For 525 
creatinine,  an endogenous, non-protein bound small molecule, a MRTexudate/MRTserum  ratio of 526 
3.6:1 was obtained by Pelligand et al. (2012a). In contrast, robenacoxib and S(+) ketoprofen 527 
MRTexudate/MRTblood ratios in the present study were substantially higher, 24.9:1 and 20.4:1 528 
respectively. These high ratios are explained by two factors, slow drug clearance from the tissue 529 
cages and short half-lives in plasma. Despite the use of tissue cages of different geometry 530 
(spherical polypropylene cages instead of silicon cylinders similar to the feline tissue cages), 531 
previous workers showed that the ketoprofen MRT ratio was also high (11.5:1) in the goat 532 
(Arifah et al., 2003) and in the calf (10.6:1) (Landoni & Lees, 1995b) though not in the horse 533 
(2.9:1). Moreover, other tissue cage investigations demonstrated that not all COXibs are tissue 534 
selective; the MRTexudate/MRTblood ratio for firocoxib in the dog (a methylsulphone related to 535 
rofecoxib) was 1.06:1 and similar to meloxicam 1.08:1 (P. Lees, unpublished data).  536 
 537 
The binding of drugs to and slow release from a component of the inflammatory process, such as 538 
protein or a specific cell population, could account for these differing results for NSAIDs 539 
(Pelligand et al., 2012b). For example, the search for the ideal radiolabelled marker for imaging 540 
COX-2 expression revealed that a radioiodinated derivative of lumiracoxib had a higher affinity 541 
and in vitro cell uptake for COX-2 induced macrophages than normal macrophages (Kuge et al., 542 
2009). A similar mechanism might explain the slow clearance of robenacoxib from exudate.  543 
The prolonged plasma half-life of the sulphonamide COXibs (celecoxib, etoricoxib and 544 
valdecoxib) is explained both by slow clearance and relatively high volume of distribution. In 545 
contrast, the volume of distribution of carboxylic acid COXibs is very small compared to other 546 
classes of COXibs. Thus, lumiracoxib steady state volume of distribution was 9 L in humans 547 
(0.13L/kg for a 70kg person, Mysler, 2004) and the distribution volume for robenacoxib was 548 
likewise low, 0.19 L/kg in the cat and 0.24 L/kg in the dog (Jung et al., 2009; Pelligand et al., 549 
2012b). 550 
 551 
The sulphonamide moiety of a radioiodinated derivative of celecoxib had a high affinity for 552 
carbonic anhydrase and this could explain both the preferential distribution into rat erythrocytes 553 
(88%) and slow clearance from blood (Boddy et al., 1989; Kuge et al., 2006). Substitution of the 554 
sulphonamide moiety to a methylsulphone moiety decreased erythrocyte binding to 18% and 555 
increased blood clearance (Kuge et al., 2006).  556 
 557 
In conclusion, the present data suggest that, despite a short blood half-life, NSAIDs can have a 558 
long-lasting local action, as a consequence of high inflammatory tissue selectivity. However, 559 
drug distribution into tissue cage fluid is model dependant and cannot be a precise predictor of 560 
penetration time course to other anatomical sites. This will indeed depend on a wide range of 561 
factors, including specific tissue blood flow and possibly the degree of acute inflammation. 562 
Tissue selectivity might be advantageous for carboxylic acids COXibs and some older NSAIDs 563 
such as ketoprofen and diclofenac, as systemic side-effects related to COX-1 and COX-2 564 
inhibition could be reduced, whilst efficacy in experimental inflammation persists for 24 h or 565 
longer after a single dose.   566 
 567 
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 739 
740 
Figure legends: 741 
Figure 1: Chemical formulae for ketoprofen and diclofenac related COXibs: lumiracoxib and 742 
robenacoxib 743 
 744 
745 
Figure 2: Observed plasma S(+) ketoprofen (●), R(-) ketoprofen (■), exudate S(+) ketoprofen (○) 746 
and exudate R(-) ketoprofen (□) concentrations (ng/mL) versus time (h) profiles after 747 
subcutaneous administration of racemic ketoprofen at a total dose of 2 mg/kg. Results from eight 748 
cats are presented as mean ±SD.  749 
 750 
Figure 3: Observed blood (●) and exudate (○) robenacoxib concentration (ng/mL) versus time 751 
(h) profiles after subcutaneous administration of a 2 mg/kg dose. Results from 8 cats are 752 
presented as mean +SD. 753 
 754 
Figure 4: Individual exudate robenacoxib concentration (ng/mL) versus time (h) profiles after 755 
subcutaneous administration of a 2 mg/kg dose. 756 
 757 
Figure 5: Exudate PGE2 concentration (ng/mL) versus time (h) profiles after carrageenan 758 
injection and placebo, racemic ketoprofen (2mg/kg total dose) and robenacoxib (2 mg/kg) 759 
subcutaneous administration. PK/PD modelling is relevant to the time-response profile as a 760 
whole rather than  to the response at sampling times taken separately and therefore values are 761 
presented as mean ±SEM. Statistical comparison of effect of treatment versus placebo (* = P 762 
<0.05) at different times (linear mixed effect model).  763 
 764 
Figure 6: Serum TxB2 concentration (ng/mL) versus time (h) profile after placebo, racemic 765 
ketoprofen (2 mg/kg total dose) and robenacoxib (2 mg/kg) subcutaneous administration. PK/PD 766 
modelling is relevant to the time-response profile as a whole rather than to the response at 767 
sampling times taken separately and therefore values are presented as mean ±SEM. Statistical 768 
comparison of effect of ketoprofen versus placebo (* = P <0.05) and robenacoxib versus placebo 769 
(£ = P <0.05) at different times (linear mixed effect model).  770 
 771 
772 
Figure 7: Observed and fitted COX inhibition (%) versus S(+) ketoprofen (red) and robenacoxib 773 
(blue) concentrations (ng/mL). Open and closed symbols represent COX-2 and COX-1, 774 
respectively. COX-1 data were rescaled for 100% Imax. In a naïve pooled data analysis, average 775 
regression curves for COX-1 and COX-2 were fitted with a sigmoid Imax model to all individual 776 
curves (n= 6 to 8 cats for each regression curve). 777 
 778 
779 
Figure 8: Inhibition percentage of COX-2 and corresponding inhibition percentages of COX-1 780 
for a range of concentration of S(+) ketoprofen and robenacoxib. Mean inhibition curves were 781 
computed by non-linear regression, fitting an average Hill equation (Imax model) to individual 782 
concentration-effect profiles (ranging from 0 to Imax and rescaled on 0-100% scales), previously 783 
obtained by solving  PK/PD models for serum TxB2 inhibition (COX-1 activity) and exudate 784 
PGE2 inhibition (COX-2 activity). Average NSAID concentrations for given inhibition 785 
percentages of COX-2 were used to determine corresponding COX-1 inhibition percentage. 786 
Dotted lines indicate cut off values for inhibition of COX-1 (above 20% inhibition of COX-1 787 
increased risk of side-effects) and COX-2 (above 80% inhibition of COX-2 correlates with good 788 
clinical efficacy). 789 
790 
Table 1. Mean pharmacokinetic parameters for plasma S(+) ketoprofen and R(-) ketoprofen and blood robenacoxib concentrations after single 791 
subcutaneous administration of racemic ketoprofen (total nominal dose of 2 mg/kg) or robenacoxib (nominal dose 2 mg/kg) in 8 healthy cats 792 
  S(+) Ketoprofen  R(-) Ketoprofen  Robenacoxib 
Parameter Unit Mean* SD or [95%CI]  Mean* SD or [95%CI]  Mean* SD or [95%CI] 
Tmax h 0.53 0.12  0.25 0.04  0.9 0.24 
Cmax ng/mL 4,306 [3,566-5,198]  3,787 [3,015-4,757]  1,313 [1,033-1,668] 
AUC0-inf ng.h/mL 8,778 [7,043-10,939]  3,082 [2,338-4,062]  3,043 [2,782-3,329] 
MRT h 1.73 0.27  0.68 0.16  1.85 0.38 
t½ h 1.62 1.14  0.44 0.19  1.13 0.18 
Vz_F L/kg 0.308 [0.192-0.495]  0.222 [0.148-0.331]  1.130 [0.949-1.344] 
CL_F L/h/kg 0.114 [0.092-0.142]  0.325 [0.246-0.428]  0.684 [0.622-0.753] 
* Tmax and MRT are presented as arithmetic mean ± SD, half lives presented as harmonic means with pseudo-SD estimated by the jackknife 793 
method. All other parameters are presented as geometric mean [95% CI of the mean], Calculation methods are given in the text. Tmax : time of 794 
maximal concentration, Cmax : maximal concentration, AUC0-inf : area under concentration versus time curve extrapolated to infinity, λz slope of 795 
the drug elimination phase and t½  corresponding elimination half life, Vz_F : volume of the central compartment scaled by bioavailability F, 796 
CL_F : body clearance scaled by bioavailability. 797 
Table 2. Mean pharmacokinetic parameters for exudate S(+) ketoprofen and R(-) ketoprofen and robenacoxib concentrations after single 798 
subcutaneous administration of racemic ketoprofen (total nominal dose of 2 mg/kg) or robenacoxib (nominal dose 2 mg/kg) in 8 healthy cats 799 
  S(+) Ketoprofen  R(-) Ketoprofen  Robenacoxib* 
 Unit Mean SD or [95%CI]  Mean SD or [95%CI]  Mean SD or [95%CI] 
Tmax h 7.9 2.35  6.0 2.55  8.1 2.79 
Cmax ng/mL 169.1 [133.5-214.1]  43.9 [34.9-55.2]  85.2 [63.1-115.1] 
t½ Kea h 2.93 2.29  2.06 1.52  4.86 2.99 
MRT h 35.89 7.41  36.22 14.85  45.68 6.07 
t½ h 25.88 3.67  22.54 12.29  41.48 8.85 
 800 
Tmax and MRT are presented as arithmetic mean ±SD, half-lives are presented as harmonic mean with pseudo-SD estimated by the jackknife 801 
method. All other parameters are presented as geometric mean [95% CI of the mean]. See text for calculation methods. Tmax is the time of 802 
maximal concentration Cmax is maximum concentration; t½ Kea and t½: half-life of penetration in exudate and elimination from exudate 803 
respectively; MRT: mean residence time in exudate calculated by non-compartmental analysis.  804 
* One cat had exceptionally high exudate robenacoxib concentration and was not included in the calculations. 805 
 806 
Table 3. Individual pharmacodynamic parameters describing the inhibitory effect of 807 
robenacoxib (2 mg/kg) and ketoprofen (2 mg/kg racemate) on exudate PGE2 production 808 
after subcutaneous administration 809 
   Robenacoxib*  Ketoprofen* 
Parameter Unit  Mean 
95%  CI or 
[range] 
 Mean 
95%  CI or 
[range] 
Kin ng/mL
/h  0.28 0.01-0.79  0.42 0.10-1.74 
Carrag no unit  33.3 11.0-100.9  10.5 4.6-24.2 
k1 /h  0.21 0.08-0.54  0.52 0.15-1.83 
k2 /h   0.05 0.03-0.10  0.03 0.02-0.05 
N no unit  2.0 1.09-3.78  1.39 0.67-2.79 
IC50 ng/mL  44.7 16.9-118.2  45.9 17.8-118.7 
Kout /h  0.12 0.04-0.39  0.16 0.09-0.29 
tlag1 (placebo) h  0.5 [0-2.9]  2.9 [0.5-7.2] 
tlag2 (NSAID) h  5.4 [0-16.5]  9.8 [0-22.0] 
An indirect response model including 9 estimated parameters was computed. 810 
* The results form 2 of 8 cats were excluded from the calculation of the mean because the 811 
inhibition of exudate PGE2 never recovered below 50% of placebo PGE2. k1 and k2: first 812 
order time dependent variables for growth and dissipation of carrageenan stimulation on 813 
COX (respectively). Carrag is a scalar, Kin is a zero-order constant for basal PGE2 814 
production, Kout is a first-order rate constant for removal of PGE2 from exudate; tlag1 and 815 
tlag2: lag time between injection of carrageenan and beginning of the carrageenan 816 
stimulation for the placebo function (tlag1) and for the NSAIDs function (tlag2). Data are 817 
reported as geometric mean with 95% CI of the mean except tlags (arithmetic mean, 818 
[range])819 
Table 4. Individual pharmacodynamic parameters describing the inhibitory effect of 820 
robenacoxib (2 mg/kg) and ketoprofen (2 mg/kg racemate) on serum TxB2 production 821 
(COX-1 activity) after subcutaneous administration. 822 
 823 
   Robenacoxib  Ketoprofen* 
Parameter Unit  Mean 95%  CI   Mean 95%  CI  
I0 ng/mL  174 115-262  201 134-301 
IC50 ng/mL  2,951 1,498-5,815  0.168 0.003-9.732 
N no unit  1.01 0.65-1.58  1.67 0.57-4.91 
 824 
*The results from two of eight cats receiving ketoprofen were excluded, as the number of 825 
samples was too low to fit a biexponential model to the blood concentration time profile. 826 
Data were fitted using a sigmoid Imax model for robenacoxib (8 cats) and ketoprofen (6 827 
cats). Imax is the percentage of maximal suppression of TxB2 (corresponding to the lower 828 
limit of quantification of the assay) relative to I0(t). I0 is the fitted value of intercept at 829 
time 0 taking into account baseline drift in TxB2 concentrations observed after placebo 830 
dosing. Data are presented as geometric mean and 95% CI of the mean for I0, IC50 and n.  831 
832 
Table 5. Average maximal effect (aImax), potency (aIC50) and slope (an) of S(+) 833 
ketoprofen and robenacoxib for ex vivo inhibition of COX-1 in serum and in vivo 834 
inhibition of COX-2 in exudate  835 
 836 
 837 
Reported parameters and bounds of the 95% confidence interval [95%CI] were calculated 838 
by naïve pooled data analysis (Giraudel et al., 2005). An average curve was fitted with a 839 
sigmoid Imax model to all simulated curves (n=8 cats for robenacoxib COX-1 and 6 cats 840 
otherwise) as if they were data from a single individual.  841 
842 
PD parameters 
Units 
aImax 
% 
 aIC50 
ng/mL 
[95%CI] 
 
 an 
(no unit) 
[95%CI] 
 
COX-1  
Ketoprofen  97.3  0.45 [0.32 - 0.65]  0.66 [0.51 - 0.81] 
Robenacoxib  96.8  2557 [2291 – 2818]  0.87 [0.80 - 0.94] 
 
COX-2  
Ketoprofen  100.0  48.5 [41.6 - 56.6]  1.04 [0.89 - 1.19] 
Robenacoxib  100.0  38.2 [33.9 - 42.7]  1.46 [1.22 - 1.70] 
Table 6. Three categories of indices describing the in vivo selectivity of robenacoxib 843 
determined by simultaneous fitting of individual percentage inhibition values from COX-844 
1 and COX-2 assays  845 
 Ketoprofen Robenacoxib 
Classical selectivity ratios:   
 IC50 / IC50     1 : 107  66.9 : 1 
 IC80 / IC80 1 : 50.4 129 : 1 
 IC95 / IC95 1 : 21.6 268 : 1 
 IC99 / IC99     1 : 8.8 585 : 1 
 IC20 / IC80 1 : 3260 1.4 : 1 
COX-1 inhibition for a given ICx COX-2::   
 % Inhibition of COX-1 at IC50 COX-2  95.7 % 2.5 % 
 % Inhibition of COX-1 at IC80 COX-2  98.2 % 5.6 % 
 % Inhibition of COX-1 at IC95 COX-2  99.3 % 12.9 % 
 % Inhibition of COX-1 at IC99 COX-2  99.7 % 28.2 % 
The data were obtained by the naïve pooled approach are reported  846 
